Eden Research plc - Thymolflex EPA approval
As the information in this release pertains to EDEN RESEARCH PLC, this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "

Eden Research Plc
("Eden" or "Company")
Thymolflex® EPA approval
Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technologies, is pleased to announce that the Company's partner, Véto-pharma, has received regulatory approval from the US Environmental Protection Agency ("EPA") for Thymolflex® for use in integrated Varroa management. Thymoflex® is a thymol-based treatment used in bee health to control Varroa destructor, an external parasitic mite that attacks and feeds on honey bees. This approval follows an announced agreement, signed by the Company in
Supporting integrated Varroa management strategies
Varroa destructor remains one of the most significant threats to honey bee health worldwide. As resistance concerns increase and environmental conditions become more unpredictable, beekeepers need multiple authorised tools that can be adapted to different colony conditions and management systems.
Thymoflex® is based on thymol, a well-known active substance of natural origin, widely used by beekeepers as part of integrated pest management (IPM) programs.
Thymoflex® is a ready-to-use thymol gel designed for straightforward handling and application in the apiary. The product allows for a controlled release of thymol within the hive, contributing to effective mite control when used according to label directions. Its formulation aims to combine ease of use, consistency, and colony safety, making it suitable for professional beekeeping operations.
By expanding access to thymol-based solutions, Thymoflex® offers beekeepers an additional option to:
· A treatment based on a naturally derived active substance
· Flexible use within the beekeeping season, according to label instructions
· Reduce reliance on a single mode of action
· Proven efficacy against varroa, including in the presence of brood
· Compatibility with treatment rotation programs, helping to manage resistance risks
· Enhance grooming behaviour and overall hygienic responses in honey bee colonies.
The gel formulation enables a homogeneous diffusion of thymol within the hive, contributing to colony safety when used according to label directions.
Availability
Thymoflex® has received EPA federal approval and will be made available to beekeepers in
More information about Thymoflex® will be available soon on the Véto-pharma website: https://www.veto-pharma.com
A long-standing commitment to honey bee health
Honeybee health is affected by multiple factors, including climate change, habitat loss, nutritional stress, pesticide exposure, and pathogens, among which varroa plays a central role. Addressing these challenges requires robust, flexible, and science-based solutions.
For more than 25 years, Véto-pharma has focused exclusively on honey bee health, developing and manufacturing products designed to support beekeepers worldwide in protecting their colonies and securing the future of pollination.
"We are delighted to be able to play such a key role in the delivery of vital care products to keep bee populations thriving. Our partnership with Véto-pharma is representative of our commitment to diversifying our business model and revenue streams by applying our sustainable chemical technology to other sectors beyond arable agriculture."
-- ENDS --
For further information, contact:
|
Eden Research plc |
|
|
|
01285 359 555 |
|
|
|
|
Cavendish Capital Markets Limited (Nominated advisor and joint broker) |
|
|
|
020 7220 0500 |
|
|
|
|
Oberon Capital (Joint Broker) |
020 3179 5300 |
|
|
|
|
Hawthorn Advisors (Financial PR) |
|
|
|
|
Notes to Editors:
About Eden Research
Eden Research is the only
For more information about Eden, visit: www.edenresearch.com.
Follow Eden on LinkedIn, Twitter and YouTube.
About Véto-pharma
Founded in 1982, Véto-pharma is a veterinary pharmaceutical laboratory dedicated to honey bee health. The company is recognised globally for its expertise, innovation, and high-quality products developed and manufactured in
For more information about Véto-pharma, visit: https://www.veto-pharma.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE